Oncology Clinical Trials Market Analysis By Industry Size, Share, Revenue Growth, Development and Demand Forecast

SDKI Inc. published a new report on the oncology clinical trial market. This study includes the statistical and analytical approaches needed to grow the oncology clinical trials market. The key industry insights provided in the report provide readers with better ideas about market overviews regarding existing market scenarios. In addition, the report contains a detailed discussion of current and future market trends related to market growth.

Report sample URL
https://www.sdki.jp/sample-request-114020

The oncology clinical trials market is expected to grow at a CAGR of 5.4% during the forecast period.

Increasing numbers of cancer cases, growing needs for personalized medicine, and high R & D spending in the pharmaceutical industry for oncology are key factors driving market growth. According to the World Health Organization (WHO), about 70% of people who died in low- and middle-income countries in 2018 were due to cancer. With this increased burden, cancer prevention is one of the most important challenges. We have also witnessed a number of unmet clinical needs in emerging countries due to the high prevalence of cancer. In addition, market growth is due to good government and non-governmental initiatives supporting cancer research.

The impact of COVID-19 on the oncology clinical trials market was negative as the number of cancer clinical trials decreased to prevent the spread of the virus. According to Emma Wilkinson's research article published in The Lancet the Journal in February 2021, clinical trials and biotherapy for new cancers were reduced by 60% during the 2020 COVID-19 pandemic.

Market segment

Oncology clinical trials The market is by phase (Phase I, Phase II, Phase III, and Phase IV), design (treatment study, observational study), cancer type (lung cancer, breast cancer, leukemia, prostate cancer, Others) and divided by region. These segments are further subsegmented based on various factors and consist of some additional information about the market, such as the combined annual growth rate of each segment and subsegment, the market value and volume of the valuation period.

Based on the type of cancer, the lung cancer segment is expected to maintain significant market growth during the forecast period. Lung cancer is caused by the uncontrolled growth of abnormal cells that grow in one or both lungs. Smokers have the highest risk of lung cancer, but they can also affect people who have never smoked. The risk of lung cancer increases with the time and number of cigarettes a patient smokes.

Regional Overview

North America is expected to dominate the market during the forecast period. Factors such as the increased burden of cancer, the presence of large outsourcing companies, and increased R & D in the region are expected to drive market growth. In North America, the impact of COVID-19 had a negative impact on the market as cancer-related clinical trials were suspended or terminated. In the United States, some biopharmacy companies such as Merck & Co. Inc. and Eli Lilly and Company have announced postponement of clinical trials.

These regional segments are North America (US and Canada); Asia Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, and other Asia Pacific); Latin America (Brazil, Mexico, Argentina, and other Latin). USA); Middle East and Africa (Israel, GCC [Saudi Arabia, Arab Emirates, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, and other Middle East and Africa) and Europe (UK, Germany, France, Italy, Spain) , Hungary, Belgium, Netherlands, Luxemburg, NORDIC, Poland, Turkey, Russia and other Europe) and more.

Major key players on the market

Key players in the oncology clinical trials market include Novartis AG, Merck & Co Inc., Bristol Myers Squibb company, F. Hoffmann-La Roche Ltd and Pfizer Inc. The study includes in-depth competitive analysis, corporate profiles, recent developments, and key market strategies for these leading companies in the oncology clinical trials market.

Details of the survey report
https://www.sdki.jp/reports/oncology-clinical-trials-market/114020

Contact Us

Hina Miyazu
15/F Cerulean Tower, 26-1 Sakuragaoka-cho
Tokyo, Shibuya-ku, Japan
+ 81345720790
sales@sdki.jp

SDKI Inc. Company Profile

SDKI Inc.'s goal is market scenarios in various countries such as Japan, China, the United States, Canada, the United Kingdom, and Germany. Is to clarify. We also focus on providing reliable research insights to clients around the world, including growth indicators, challenges, trends and competitive environments, through a diverse network of research analysts and consultants. With SDKI gaining trust and a customer base in more than 30 countries, SDKI is even more focused on expanding its foothold in other pristine economies.

This release was published on openPR.